Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020901 | 0.89 | GSK3A (0.39) | DCUN1D1ALPLGSK3BGSK3ACNR1 | |
| SCHEMBL5097334 | 0.84 | GSK3B (0.40) | DCUN1D1ALPLGSK3BGSK3ACNR1 | |
| SCHEMBL5107013 | 0.83 | DCUN1D1 (0.42) | DCUN1D1ALPLGSK3BGSK3ACNR1 | |
| SCHEMBL5093625 | 0.81 | GSK3B (0.40) | DCUN1D1GSK3BGSK3AHAO1CNR1 | |
| SCHEMBL4011970 | 0.81 | AURKA (0.47) | DCUN1D1ALPLGSK3BGSK3AAURKA | |
| SCHEMBL14038968 | 0.81 | HAO1 (0.33) | HAO1CHRNA7 | |
| SCHEMBL3254089 | 0.76 | IGF1R (0.41) | ALPLGSK3BGSK3AAURKAAURKB | |
| SCHEMBL5097291 | 0.75 | MAPK14 (0.46) | GSK3BGSK3APIM1AURKA | |
| SCHEMBL16447913 | 0.72 | AURKA (0.43) | DCUN1D1GSK3BGSK3ACNR1AURKA | |
| SCHEMBL5107082 | 0.70 | MAPK14 (0.44) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | claimed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | claimed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | DCUN1D1 2414/4885ALPL 4785/4885GSK3B 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.